Hansoh Pharmaceutical (3692.HK) — Quick Take

Healthcare is the dominant sector in both VolumeSurge screeners — 13 of 50 HK names and 28 of 50 US names on the 26–27 Aug scans. Hansoh (3692.HK) is the #2 HK pick for Thu 27 Aug and the biggest single-day mover among the top picks, up +16.0% on HK$1.2B turnover, after its board approved H1 2026 interim results and an interim dividend on 26 Aug. The stock closed at HK$36.82, back toward the top of its 52-week range (HK$28.06–44.22).

Financial Snapshot

FY2025 revenue reached RMB 15.03B (+22.6% YoY) with net profit of RMB 5.56B, comfortably beating the ~RMB 4.97B LSEG consensus. Innovative and collaborative drug revenue hit RMB 12.35B — now 82.2% of the total, up from roughly half just two years ago. R&D spending runs near 20% of revenue, funding a deep ADC, bispecific and GLP-1/metabolic pipeline.

Bull vs Bear

Year	Revenue (RMB B)	Rev Growth	Net Margin	Net Income (RMB B)
2022	9.34	-6.1%	27.6%	2.58
2023	10.10	+8.2%	32.4%	3.28
2024	12.26	+21.4%	35.5%	4.35
2025	15.03	+22.6%	37.0%	5.56
H1 2026	—	—	—	reported 26 Aug

✅ Bull Case

Innovation flywheel: innovative/collaborative drug revenue is now 82% of the mix and compounding, driving net margin from ~28% to 37% in three years.
Global validation: $4.5B+ of overseas licensing — GSK's B7-H3 ADC (HS-20093/risvutatug rezetecan) just posted a second Phase III win (bone cancer), and Merck/MSD holds the oral GLP-1 (HS-10535).
Momentum + beat: FY2025 profit beat consensus by ~12%; H1 2026 results + interim dividend drove a +16% single-day re-rating amid a Healthcare-led tape.

🔴 Bear Case

China pricing risk: NRDL reimbursement cuts and VBP pressure on the legacy generics base can drag near-term top-line growth.
Rich multiple: at ~27–34x earnings the market is already paying for pipeline execution; a clinical setback in ADC/GLP-1 assets would de-rate the stock fast.
Concentration & lumpiness: revenue is still China-mainland-dominated and BD milestone timing can make quarters uneven, with a handful of key assets carrying the growth.

Verdict

Hansoh has quietly completed the generics-to-innovation transformation — 82% of revenue is now innovative drugs, and GSK and Merck licensing deals have put its ADC and metabolic pipeline on the global map. The post-interim-results +16% move is momentum backed by a real earnings beat, but at ~US$25B and ~27x forward earnings much of the good news is already priced in. It's a high-quality China healthcare-innovation compounder worth watching; the near-term risk is valuation and the binary nature of its clinical pipeline.